Mild nausea is the most common side effect and is seen in approximately 30% of people taking<unk>  though this rarely (<3%) results in discontinuation of the medication. Other less common side effects include headache, difficulty sleeping, and vivid dreams. Rare side effects reported by people taking<unk>  compared to placebo include change in taste, vomiting, abdominal pain, flatulence, and constipation. It has been estimated that for every five subjects taking<unk>  at maintenance doses, there will be an event of nausea, and for every 24 of 35 treated subjects, there will be an event of constipation and flatulence, respectively. Gastrointestinal side-effects lead to discontinuation of the drug in 2% to 8% of people using<unk> . Incidence of nausea is dose-dependent: incidence of nausea was higher in people taking a larger dose (30%) versus placebo (10%) as compared to people taking a smaller dose (16%) versus placebo (11%). Depression and suicide In 2007, the US FDA had announced it had received post-marketing reports of thoughts of suicide and occasional suicidal behavior, erratic behavior, and drowsiness among people using<unk>  for smoking cessation. In 2009, the US FDA required<unk>  to carry a boxed warning that the drug should be stopped if any of these symptoms are experienced. A 2014 systematic review did not find evidence of an increased suicide risk. Other analyses have reached the same conclusion and found no increased risk of neuropsychiatric side effects with<unk> . No evidence for increased risks of cardiovascular events, depression, or self-harm with<unk>  versus nicotine replacement therapy was found in one post-marketing surveillance study. In 2016 the FDA removed the black box warning. People are still advised to stop the medication if they "notice any side effects on mood, behavior, or thinking." Cardiovascular disease In June 2011, the US FDA issued a safety announcement that<unk>  may be associated with "a small, increased risk of certain cardiovascular adverse events in people who have cardiovascular disease." A prior 2011 review had found increased risk of cardiovascular events compared with placebo. Expert commentary in the same journal raised doubts about the methodology of the review, concerns which were echoed by the European Medicines Agency and subsequent reviews. Of specific concern were "the low number of events seen, the types of events counted, the higher drop-out rate in people receiving placebo, the lack of information on the timing of events, and the exclusion of studies in which no-one had an event." In contrast, multiple recent systematic reviews and meta-analyses have found no increase in overall or serious adverse cardiovascular events (including for individuals at risk of developing cardiovascular disease) associated with<unk>  use.
Varenicline
Seltorexant
Ambulatist
Veristrat
Vernakalant
Suvorexant
Icatibant
Daridorexant